ライフサイエンスコーパス: glycate

1 Forty-five glycated, 48 advanced glycation endproduct (AGE-) modifi

2 herapeutic approaches against neurotoxic CEL-glycated Abeta1-42.

3 es the metabolism of reactive metabolite and glycating agent methylglyoxal-may improve metabolic and

4 Methylglyoxal (MG), an arginine-directed glycating agent, is implicated in diabetic late complica

5 cations of diabetes where increased reactive glycating agent, methylglyoxal (MG), is involved.

6 eins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in the blood, are essential indica

7 an HbA1c in meta-analysis (P = 0.0225), mean glycated albumin (P = 0.0029), and glyoxal hydroimidazol

8 We measured glycated albumin and fructosamine in 11 104 participants

9 ifferences were found in the relationship of glycated albumin and fructosamine levels with the mean g

10 Fructosamine and glycated albumin are markers of short-term glycemic cont

11 We found that fructosamine and glycated albumin were associated with vascular outcomes

12 baseline concentrations of fructosamine and glycated albumin were significantly associated with each

13 e evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, is

14 , glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney func

15 monitoring and compared by race with HbA1c, glycated albumin, and fructosamine values.

16 FK is the epsilon-fructosyl amino acid from glycated albumin, another glycated protein, whereas gluc

17 d fasting glucose, insulin, adiponectin, and glycated albumin, as well as body mass index (BMI), use

18 enabling separation of positional isomers of glycated alpha- and beta-chains on the intact level.

19 The percentage of glycated alpha-Hb and beta-Hb was calculated from the mi

20 case that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins by acting on early gly

21 nes, arginines, and lysines (the three major glycated amino acids) of serum albumin, glyceraldehyde-3

22 nchmark dataset was extracted containing 235 glycated and 303 non-glycated lysine residues.

23 based on support vector machine, to predict glycated and non-glycated lysine residues using structur

24 The proposed predictor manages to classify glycated and non-glycated lysine residues with promising

25 nine sites, as well as by converting already-glycated arginine residues into citrulline.

26 A second glycated beta-Hb isomer that is partially resolved from

27 The values for glycated beta-Hb were found to correlate well with the H

28 n is achieved between alpha-Hb, beta-Hb, and glycated beta-Hb.

29 ected in extracted ion electropherograms for glycated beta-Hb.

30 Measurement of glycated blood proteins, particularly glycated hemoglobi

31 glycated chaperone-client complexes than in glycated but uncomplexed protein mixtures.

32 backbone conformation from A to B form when glycated, but does not induce any final transition in DN

33 Proteins were glycated by incubation with sugars (glucose, methylglyox

34 protein isolates that had been denatured and glycated by thermal treatment.

35 inking AGEs were significantly higher in the glycated chaperone-client complexes than in glycated but

36 Glycated collagen 1 and AGE-modified ECM regulate adipoc

37 en fibrils and, using KFM and FLiM, that R5P-glycated collagen fibrils have a more negative surface c

38 e extracellular matrix structure surrounding glycated collagen fibrils.

39 indicated the formation of hydrolysates and glycated compounds with different molecular weight distr

40 on products (MRPs), protein hydrolysates and glycated compounds.

41 To prepare glycated cowpea protein isolate (GCPI) the cowpea flour

42 By using ESI-QTOF-MS technique, formation of glycated cytochrome C containing up to 12 glucose moieti

43 terial mutants displayed increased levels of glycated DNA and RNA and exhibited strong mutator phenot

44 e for a rapid and reliable identification of glycated DNA in a reagent-free manner.

45 in contrast to guanine oxidation repair, how glycated DNA is repaired remains undetermined.

46 ws a clear discrimination between native and glycated DNA samples.

47 depleted cells displayed increased levels of glycated DNA, DNA strand breaks, and phosphorylated p53.

48 e process where proteins accumulate advanced glycated end products (AGEs).

49 indicated a significant decrease in advance glycated end products and protection against glycoxidati

50 Hyperglycemia and exposure to advanced glycated end products inactivated MFG-E8, recognizing a

51 lysates showed reduced fluorescence advanced glycated end-products (AGE) and a reduced amount of alph

52 insulin signaling, accumulation of advanced glycated end-products, altered autophagy, changes in myo

53 e-associated molecular patterns and advanced glycated endproducts and can trigger cell activation.

54 esized that restoring the levels of Hsp27 in glycating environments could alleviate the pathogenicity

55 Our findings suggest that in glycating environments, the levels of Hsp27 are importan

56 Amadori rearrangements and the free and mono-glycated guanidine also formed imidazolinone derivatives

57 diabetes remission at 2 years, defined as a glycated haemaglobin A1c (HbA1c) concentration of 6.5% o

58 ive treatments for type 2 diabetes, lowering glycated haemoglobin (HbA(1c)) and weight, but are curre

59 years, diagnosed with type 2 diabetes with a glycated haemoglobin (HbA(1c)) concentration of 7.5% or

60 Glycated haemoglobin (HbA(1c)) is considered the gold st

61 erol <=4 mmol/L, triglycerides <=1.7 mmol/L, glycated haemoglobin (HbA1c) <=53 mmol/mol (<=7.0%), sys

62 more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6.5% (<48 mmol

63 lucose (FBS), random blood glucose (RBS), or glycated haemoglobin (HbA1c) were reported.

64 Mean changes in glycated haemoglobin (HbA1c), and mean changes in fastin

65 lthough associations between multimorbidity, glycated haemoglobin (HbA1c), and mortality in people wi

66 nge glucose and insulin measures, as well as glycated haemoglobin (HbA1c), are used to diagnose and m

67 and intensification: age, sex, deprivation, glycated haemoglobin (HbA1c), body mass index (BMI), smo

68 lso associated with improvements in glucose, glycated haemoglobin (HbA1c), weight, waist circumferenc

69 n delivery (pump or injections) and baseline glycated haemoglobin (HbA1c).

70 density-lipoprotein cholesterol (HDL-C), and glycated haemoglobin (HbA1c).

71 eins [LDL and HDL], triglycerides [TGs], and glycated haemoglobin [HbA1c]).

72 abetes at high cardiovascular risk with high glycated haemoglobin A(1c) (HbA(1c)) concentrations.

73 prior to enrolment, and centrally confirmed glycated haemoglobin A1c (HbA(1c)) of 48-58 mmol/mol (6.

74 The primary outcome was a change in glycated haemoglobin A1c (HbA1c) from baseline to week 2

75 function, lipid profile, glucose tolerance, glycated haemoglobin A1c, salivary cortisol, sitting hei

76 and additional cardiovascular risk factors, glycated haemoglobin of up to 9.5% (80 mmol/mol) on a ma

77 Changes in fasting glucose and glycated haemoglobin were not different between groups a

78 The changes in glycated haemoglobin, as the primary outcome, in the pro

79 iles (longer duration of diabetes and higher glycated haemoglobin, non-HDL cholesterol, and waist-to-

80 least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium measurements between Oc

81 sure, body-mass index, total cholesterol and glycated-haemoglobin levels.

82 It was observed that patients with elevated glycated Hb levels also had higher levels of HSA glycati

83 Quantification of glycated Hb was in good correlation with the results obt

84 In clinical routine analysis of glycated Hb, sequence variants or other Hb proteoforms c

85 nctive test lines when challenged with HbA0, glycated HbA0 and HbA2.

86 ss index (47.6+/-9.3 to 36.7+/-7; P<0.0001), glycated hemoglobin (6.7+/-1.5 to 5.8+/-0.6; P<0.0001),

87 liflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points

88 Improved glycated hemoglobin (Hb A1c) delays the progression of m

89 oad glucose (PG), 2-h postload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model asse

90 Glycated hemoglobin (HbA(1c)) is an important measure of

91 08) while controlling for age, sex, baseline glycated hemoglobin (HbA(1c)), baseline CMT, baseline VA

92 es diagnosis, serum fasting glucose (FG) and glycated hemoglobin (HbA(1c)), were estimated to be 51-6

93 om among 321 people with type 2 diabetes and glycated hemoglobin (HbA1c) >58 mmol/mol.

94 ype 2 diabetes were recruited: subjects with glycated hemoglobin (HbA1c) </=7% and subjects with HbA1

95 ; betaPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (betaPFOS=0.03%; 95% CI: 0.0

96 ) concentration (-37.0 mg/dL; P < 0.001) and glycated hemoglobin (HbA1c) [-0.97% (-10.6 mmol/mol); P

97 a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007)

98 ulinemia, decreased C-peptide, and increased glycated hemoglobin (HbA1c) compared with sham-operated

99 d the association between food label use and glycated hemoglobin (HbA1c) concentrations.

100 After 12 months, glycated hemoglobin (HbA1c) decreased from 10.3+/-2.4% t

101 has been developed for the determination of glycated hemoglobin (HbA1c) in human blood samples.

102 The level of Glycated hemoglobin (HbA1c) is accordingly examined for

103 Glycated hemoglobin (HbA1c) is used to diagnose type 2 d

104 ex, waist circumference, fat percentage, and glycated hemoglobin (HbA1c) level were recorded chairsid

105 n leakage area at month 36 (P = 0.0137), and glycated hemoglobin (HbA1c) levels at month 36 (P = 0.00

106 (20-50 U) and metformin (>/=1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a bo

107 nfluence of periodontal status on changes of glycated hemoglobin (HbA1c) levels of patients with type

108 igated OCT-A parameters with DM duration and glycated hemoglobin (HbA1c) levels were evaluated among

109 Glycated hemoglobin (HbA1c) levels were measured, and pr

110 2 spectral domain OCT (SD-OCT) tests, and 2 glycated hemoglobin (HbA1c) measures over time with a mi

111 DM prevalence was estimated using laboratory glycated hemoglobin (HbA1c) or fasting plasma glucose in

112 Glycated proteins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in

113 hievement of good glycemic control, of which glycated hemoglobin (HbA1c) remains the standard clinica

114 An immunoassay for detection of glycated hemoglobin (HbA1c) that can reveal a patient's

115 in or loss and glycemic control (assessed by glycated hemoglobin (HbA1c) values) in patients from the

116 In multivariable analyses, glycated hemoglobin (HbA1c) was inversely associated wit

117 Higher levels of glycated hemoglobin (HbA1c) were associated with all-cau

118 rmined for fasting glucose, fasting insulin, glycated hemoglobin (HbA1c), and homeostasis model asses

119 tion of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovasc

120 The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and ga

121 eplacement of other sugars and its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insu

122 agnostic accuracies of random blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostas

123 glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albu

124 triacylglycerol (TG), fasting glucose (FG), glycated hemoglobin (HbA1c), insulin resistance (HOMA-IR

125 and at follow-up, was associated with higher glycated hemoglobin (HbA1c), insulin, HOMA-IR, triglycer

126 ent of glycated blood proteins, particularly glycated hemoglobin (HbA1c), is an important diagnostic

127 Blood glycated hemoglobin (HbA1c), reflecting the average bloo

128 ed with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeostasis model asses

129 Measurement of glycated hemoglobin (HbA1c), the most widely accepted in

130 blood pressure (BP), fasting blood glucose, glycated hemoglobin (HbA1c), triglyceride levels, trigly

131 led trials (RCTs) that assessed the outcomes glycated hemoglobin (HbA1c), weight, body mass index (BM

132 sensor was developed for the recognition of glycated hemoglobin (HbA1c).

133 body mass index (in kg/m(2)): 34.6 +/- 4.3; glycated hemoglobin (HbA1c): 7.3 +/- 1.1%; duration of d

134 n [n = 136; mean +/- SD age: 12.8 +/- 2.6 y; glycated hemoglobin (HbA1c): 8.1% +/- 1.0%; 69.1% using

135 .7%) was associated with a reduction in mean glycated hemoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), f

136 In 2006, 56% of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the

137 Levels of blood glucose/glycated hemoglobin (International Federation of Clinica

138 How these risks vary with glycated hemoglobin (or hemoglobin A1c [HbA1c]) levels i

139 ion was associated with a higher increase in glycated hemoglobin (P = 0.027).

140 luble leptin receptor (reduction of 43%) and glycated hemoglobin (reduction of 28%).

141 97 individuals >=40 and <=80 years old with glycated hemoglobin 6.5% to 10.0%, known coronary artery

142 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.0% +/- 0.8%; body mass index (in k

143 8 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/=8% during the year) while

144 tensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established

145 cose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung tr

146 fication by sex, history of ischemic stroke, glycated hemoglobin A(1c), body mass index, blood pressu

147 g plasma glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported phy

148 se [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, an

149 agnosis, sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

150 While adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we fou

151 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 2

152 ciation of baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selec

153 The only significant predictor of glycated hemoglobin A1c reduction was waist circumferenc

154 are well-adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mell

155 s largely determined by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects d

156 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin we

157 We collected data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, s

158 tions, pain (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, bo

159 s there exists a direct relationship between glycated hemoglobin and cardiovascular disease (CVD), cl

160 All participants were screened for DM using glycated hemoglobin and fasting plasma glucose at TB tre

161 ic red blood cells correlates with levels of glycated hemoglobin and that the mechanical properties o

162 of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account f

163 iculated thrombocytosis that correlates with glycated hemoglobin as well as increased plasma S100A8/A

164 ing age, absence of epiretinal membrane, and glycated hemoglobin below 9 as predictive of DR ultra-re

165 ears after baseline on the basis of either a glycated hemoglobin concentration of at least 6.5% or us

166 studies that have demonstrated reductions in glycated hemoglobin concentration.

167 ng an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI,

168 ed 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy

169 nly during the prolonged period in which the glycated hemoglobin curves were separated.

170 s improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol a

171 Glycated hemoglobin decreased significantly from 8.2 +/-

172 h both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providin

173 and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.CCK r

174 closures do not affect health in general, 2) glycated hemoglobin is insensitive to local foreclosure

175 52.5 vs 54.8 years), BMI (45.1 vs 42.6), and glycated hemoglobin level (7.1% vs 7.1%).

176 wer; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0

177 , 1.02; 95% CI, 1.01-1.04) and knowing one's glycated hemoglobin level (odds ratio, 2.00; 95% CI, 1.3

178 , sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.

179 uration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%.

180 nd point was the change from baseline in the glycated hemoglobin level after 26 weeks.

181 The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 perce

182 index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the p

183 The primary end point was the change in glycated hemoglobin level from baseline to week 26.

184 of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percenta

185 The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, wi

186 n, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe

187 with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%.

188 was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% o

189 The primary outcome was a glycated hemoglobin level of 6.0% or less with or withou

190 diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and an oxygen des

191 ients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (</=52 mmol pe

192 ng those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared w

193 ed hemoglobin level score [calculated as the glycated hemoglobin level plus 4 times the insulin dose]

194 of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%.

195 e patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye e

196 esponse (defined as an insulin dose-adjusted glycated hemoglobin level score [calculated as the glyca

197 r mean percentage reduction from baseline in glycated hemoglobin level than did patients who received

198 e estimated mean change from baseline in the glycated hemoglobin level was -1.33 percentage points in

199 The mean (SD) glycated hemoglobin level was 7.4% (0.5%).

200 At 24 months, the mean glycated hemoglobin level was 7.5+/-1.2% in each group,

201 similar in the two groups; the mean baseline glycated hemoglobin level was 8.09% in the icodec group

202 iabetes was 16.4 years, and the mean (+/-SD) glycated hemoglobin level was 8.4+/-1.7%; 83.9% of the p

203 s 16.1 years (range, 2-36 years), and median glycated hemoglobin level was 8.8% (IQR, 7.4%-10%).

204 s was 49+/-8 years, 66% were women, the mean glycated hemoglobin level was 9.2+/-1.5%, and the mean B

205 hich patients with type 2 diabetes mellitus (glycated hemoglobin level, >=7%), chronic kidney disease

206 ucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%) and no diagnosti

207 type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking met

208 etes had poor glycemic control (mean [+/-SD] glycated hemoglobin level, 9.0+/-2.4%), and the rates of

209 s >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that t

210 itional end points included insulin use, the glycated hemoglobin level, the number of hypoglycemic ev

211 points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressu

212 C-peptide levels, insulin requirements, and glycated hemoglobin level.

213 lycemia, and, in adults, resulted in a lower glycated hemoglobin level.

214 1.13; P = .003) for each unit of increase in glycated hemoglobin level.

215 counting for glycemic control in the form of glycated hemoglobin level.

216 significant difference between the groups in glycated hemoglobin level.

217 t did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI,

218 f 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean differenc

219 The phenomenon of a discrepancy between glycated hemoglobin levels and other indicators of avera

220 loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 t

221 The difference in glycated hemoglobin levels between the intensive-therapy

222 previously been found to reduce glucose and glycated hemoglobin levels in humans.

223 e fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

224 Glycated hemoglobin levels were lower with pump therapy

225 Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass

226 men, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

227 progression was also closely related to mean glycated hemoglobin levels.

228 al history, antidiabetic medication use, and glycated hemoglobin levels.

229 c blood pressures, and high triglyceride and glycated hemoglobin levels.

230 amer-based microfluidic system for automatic glycated hemoglobin measurements.

231 /m(2)) of 39.2 (95% CI: 35.2, 43.3) and mean glycated hemoglobin of 5.3% (95% CI: 4.9%, 5.6%), were s

232 Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardio

233 We used admission glycated hemoglobin to estimate premorbid baseline blood

234 lar disease (CVD), clinical trials targeting glycated hemoglobin to near-normal levels using intensiv

235 ological factors assessed, insulin index and glycated hemoglobin values explained 15% and 16% of the

236 mm Hg; -9.0, -2.7 mm Hg) diets, and reduced glycated hemoglobin with the Mediterranean diet (-0.8 mm

237 rs are modestly effective in reducing HbA1c (glycated hemoglobin) ( approximately 0.5%) and while the

238 inal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin), and systolic blood pressure were o

239 Thirteen people with T2DM (glycated hemoglobin, 6.9+/-1.0%) and 12 age-matched heal

240 an age, 64.0 years; 2414 [39.9%] women; mean glycated hemoglobin, 7.2%; median duration of diabetes,

241 ysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex.

242 syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric

243 cholesterol, triglycerides, blood pressure, glycated hemoglobin, and fasting glucose and report the

244 ar reductions in insulin, insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of

245 ymptoms and changes in the levels of lipids, glycated hemoglobin, and prolactin were similar in the t

246 e intervention group had significantly lower glycated hemoglobin, fasting plasma glucose, plaque inde

247 cant between-group differences were found in glycated hemoglobin, HDL-cholesterol, or triglyceride co

248 justment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholestero

249 rly high-density lipoprotein cholesterol and glycated hemoglobin, led to a greater degree of attenuat

250 For every 1% higher glycated hemoglobin, left ventricular mass was higher by

251 cident CKD included BP >140/90 mm Hg, higher glycated hemoglobin, lower baseline eGFR, and higher bas

252 ptical coherence tomography, blood pressure, glycated hemoglobin, medications, and changes in such pa

253 positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment le

254 adjusting for age, waist-to-hip ratio (WHR), glycated hemoglobin, smoking, education, and grip streng

255 e foreclosure rate per census-block group on glycated hemoglobin.

256 block group in the prior year and changes in glycated hemoglobin.

257 een the study groups were seen for change in glycated hemoglobin.

258 s-related traits such as fasting glucose and glycated hemoglobin.

259 f signals while varying concentration of the glycated hemoglobin.

260 corresponding reduction in the percentage of glycated-hemoglobin to levels similar to lean, healthy m

261 d by measurement of the cutoff ratio between glycated hemoglobins (HbA1c) and total hemoglobin (Hb),

262 ntified peptides in the enriched fraction as glycated, high sensitivity for detection of glycated pep

263 1c levels did not have the highest levels of glycated HSA.

264 of glycated peptides quantified in in vitro glycated human plasma increased more than 3-fold using t

265 and modified DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an interme

266 The glycated hydrolysates showed reduced fluorescence advanc

267 We chemically synthesized glycated IAPP (AGE-IAPP) to mimic the consequence of thi

268 We also noted a decrease in glycated lysine residues in collagen, indicating that th

269 vector machine, to predict glycated and non-glycated lysine residues using structural properties of

270 edictor manages to classify glycated and non-glycated lysine residues with promising results consiste

271 xtracted containing 235 glycated and 303 non-glycated lysine residues.

272 trast, only 168 polypeptides contained early glycated lysines, which did not resemble the sites of ad

273 YajL could repair methylglyoxal- and glyoxal-glycated nucleotides and nucleic acids.

274 e 2D-LC-HCD-MS/MS platform for comprehensive glycated peptide quantification.

275 line platform to human plasma identified 376 glycated peptides from 10 mug of protein digests.

276 The number of glycated peptides quantified in in vitro glycated human

277 glycated, high sensitivity for detection of glycated peptides with LOD and LOQ at 1.2 and 2.4 pg, re

278 ility with interday CVs < 20% for 80% of the glycated peptides.

279 ool for identification and quantification of glycated peptides.

280 rabidopsis thaliana The absence of the early glycated precursors of the AGE-modified protein residues

281 oducible online 2D platform is promising for glycated protein analysis of complex clinical samples.

282 n in exposed splenocyte, were evident in the glycated protein treated mice as compared to its native

283 Thereafter, allergic behaviour of this glycated protein was compared with its native form, usin

284 The reduced allergenicity of glycated protein was observed as lesser allergic phenoty

285 yl amino acid from glycated albumin, another glycated protein, whereas glucose is naturally present a

286 Glycated proteins are emerging as good indicators for di

287 Although the patterns of glycated proteins were only minimally influenced by plan

288 hree aging-specific and eight differentially glycated proteins, four of which were modified in cataly

289 Glycated proteins, such as glycated hemoglobin (HbA1c) o

290 However, the platform for analysis of glycated proteome has been relatively less well establis

291 -related changes in the Arabidopsis thaliana glycated proteome, including the proteins affected and s

292 Dry and subsequent wet heating were used to glycate soy proteins with dextran or glucose, followed b

293 to 12 glucose moieties were observed, while glycated species containing 6 and 8 glucose moieties wer

294 rameters with the levels of glycosylated and glycated species in a series of small scale experiments,

295 proteoforms, including positional isomers of glycated species in a single run.

296 The glycated species of cytochrome C, lysozyme, and beta-cas

297 Cytochrome C had multiple charges in non-glycated state, primarily changing from +13 to +17 posit

298 In its absence, NRF2 is extensively glycated, unstable, and defective at binding to small MA

299 ocess (ISP) was hydrolysed with Alcalase and glycated with glucosamine (GlcN) at moderate temperature

300 rmal stability and antioxidative capacity of glycated WP were increased, especially in the presence o